Biogen Inc. $BIIB Stock Position Raised by National Pension Service

National Pension Service grew its holdings in Biogen Inc. (NASDAQ:BIIB) by 1.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 406,064 shares of the biotechnology company’s stock after purchasing an additional 4,397 shares during the period. National Pension Service’s holdings in Biogen were worth $87,734,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of BIIB. California State Teachers Retirement System raised its position in Biogen by 21,439.6% during the second quarter. California State Teachers Retirement System now owns 47,535,145 shares of the biotechnology company’s stock valued at $10,270,443,000 after buying an additional 47,314,458 shares during the period. BlackRock Inc. purchased a new stake in Biogen in the 2nd quarter worth about $3,453,878,000. Primecap Management Co. CA acquired a new stake in Biogen during the 2nd quarter worth about $3,274,304,000. Norges Bank purchased a new position in Biogen during the 4th quarter valued at about $464,408,000. Finally, Boston Partners purchased a new position in Biogen during the fourth quarter valued at approximately $302,815,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Trading Up 0.8%

NASDAQ:BIIB opened at $217.15 on Friday. The company’s 50 day moving average is $209.57 and its 200-day moving average is $197.36. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen Inc. has a 12 month low of $135.39 and a 12 month high of $225.80. The firm has a market cap of $32.08 billion, a price-to-earnings ratio of 38.43, a P/E/G ratio of 2.38 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.94 by $0.66. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. Biogen’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities analysts anticipate that Biogen Inc. will post 12.39 EPS for the current year.

Analyst Ratings Changes

BIIB has been the topic of a number of recent research reports. Bank of America lowered their target price on Biogen from $217.00 to $215.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 21st. TD Cowen increased their price objective on Biogen from $215.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Citigroup raised their price objective on shares of Biogen from $200.00 to $215.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Piper Sandler reiterated an “overweight” rating and issued a $245.00 target price (up from $225.00) on shares of Biogen in a research note on Thursday, September 3rd. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Biogen in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $230.14.

Biogen Profile

Biogen Inc is a biotechnology company focused on discovering, developing and commercializing therapies for neurological and neurodegenerative diseases. Founded in 1978, the company is headquartered in Cambridge, Massachusetts, and serves patients and healthcare providers in markets around the world.

Biogen’s portfolio includes treatments for multiple sclerosis, including Tecfidera, Vumerity, Tysabri, Avonex and Plegridy, as well as Spinraza for spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals.